The findings show how more rapid results can improve practice and lead to more accurate and timely diagnoses

Results led to expanded FDA approval in January 2024.

The large study also confirmed known risk factors for COVID-19 associated with asthma in children.

The first patient with this specific autoimmunity disorder was identified at CHOP.

A 16-week course could increase the threshold of peanut, tree nuts, egg, milk and wheat that would trigger an allergic reaction.

In the largest study of its kind, CHOP researchers have validated a population-level pattern of pediatric allergy development known as the “allergic march.”

CHOP researchers have shown that IgA acts as a “tuner” that regulates the number of microbes the body sees every day, restraining a systemic immune response.

A CHOP-led study has shown that a regulatory class of T cells descends from two different origins, one that relates to autoimmunity and one that relates to protective immunity.

A new study involving CHOP researchers found that daily use of a “peanut patch” for one year was effective in desensitizing a majority of peanut-allergic toddlers.

A new study in the Annals of Allergy, Asthma & Immunology shows that a first-of-its-kind program at CHOP can help children with food allergy-related anxiety reduce their fears and improve their quality of life.